| Christophi GP, Panos M, Hudson CA, et al.
Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1. [JOURNAL ARTICLE]
Clin Immunol 2009 Jun 24.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Rudick RA, Pace A, Rani MR, et al.
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
Neurology 2009 Jun 9; 72(23):1989-93.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| O'Connor P, Kinkel R, Kremenchutzky M
Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. [JOURNAL ARTICLE]
Mult Scler 2009 Jun; 15(6):728-734.
Abstract | Full Citation | Find Related Articles |
| Putzki N, Fischer J, Gottwald K, et al.
Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. [Journal Article]
Eur J Neurol 2009 Jun; 16(6):713-20.
Abstract | Full Citation |
| Kauffman MA, Yankilevich P, Barrero P, et al.
Whole genome analysis of the action of interferon-beta. [Journal Article]
Int J Clin Pharmacol Ther 2009 May; 47(5):328-57.
Abstract | Full Citation | Find Related Articles |
| Havrdova E, Zivadinov R, Krasensky J, et al.
Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. [JOURNAL ARTICLE]
Mult Scler 2009 May 22.
Abstract | Full Citation | Find Related Articles |
| Boster A, Racke MK
Pharmacotherapy of multiple sclerosis: the PROOF trial. [Journal Article]
Expert Opin Pharmacother 2009 Jun; 10(8):1235-7.
Abstract | Full Citation | Publisher Full Text |
| de Andrés C, Aristimuño C, Bartolomé M, et al.
Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4(+) regulatory T-cells in relapsing-remitting multiple sclerosis: A 1-year longitudinal study. [JOURNAL ARTICLE]
J Neuroimmunol 2009 May 14.
Abstract | Full Citation |
| Hernandez-Perez MA, En Representacion Del Grupo de Investigadores Del Estudio Paralen ER
[Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study).] [English Abstract, Journal Article]
Rev Neurol 2009 May 16-31; 48(10):505-8.
Abstract | Full Citation | Find Related Articles |
| Chiao E, Meyer K
Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. [JOURNAL ARTICLE]
Curr Med Res Opin 2009 May 7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
  |
